Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 12.02B | 11.49B | 11.42B | 10.88B | 11.21B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.02B | 11.49B | 11.42B | 10.88B | 11.21B |
| Cost of Revenue | 2.30B | 2.06B | 1.92B | 1.77B | -872.00M |
| Gross Profit | 9.73B | 9.44B | 9.50B | 9.11B | 12.08B |
| SG&A Expenses | 4.89B | 4.44B | 5.05B | 4.15B | 4.02B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -131.00M | -70.00M | -784.00M | -39.00M | -71.00M |
| Total Operating Expenses | 9.99B | 8.96B | 8.81B | 8.19B | 5.51B |
| Operating Income | 2.03B | 2.53B | 2.60B | 2.69B | 5.70B |
| Income Before Tax | 897.00M | 1.65B | 2.09B | 2.26B | 778.00M |
| Income Tax Expenses | -62.00M | 274.00M | 268.00M | 458.00M | -124.00M |
| Earnings from Continuing Operations | 959.00M | 1.38B | 1.82B | 1.80B | 902.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00M | -4.00M | -2.00M | -1.00M | -1.00M |
| Net Income | 960.00M | 1.37B | 1.82B | 1.80B | 901.00M |
| EBIT | 2.03B | 2.53B | 2.60B | 2.69B | 5.70B |
| EBITDA | 2.93B | 3.76B | 3.83B | 3.92B | 6.67B |
| EPS Basic | 0.62 | 0.89 | 1.17 | 1.16 | 0.58 |
| Normalized Basic EPS | 0.70 | 0.90 | 0.90 | 0.97 | 2.18 |
| EPS Diluted | 0.61 | 0.88 | 1.17 | 1.16 | 0.58 |
| Normalized Diluted EPS | 0.70 | 0.89 | 0.89 | 0.96 | 2.17 |
| Average Basic Shares Outstanding | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B |
| Average Diluted Shares Outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Dividend Per Share | 1.97 | 0.00 | 0.93 | -- | 1.97 |
| Payout Ratio | 0.21% | 102.62% | 1.21% | 169.00% | 0.00% |